NewsBenzingaZenas BioPharma presentará nuevos datos del ensayo de fase 3 INDIGO que evalúa Obexelimab en la enfermedad relacionada con IgG4 en el 6º Simposio Internacional sobre la Enfermedad Relacionada con IgG4, y en la Convergencia ACR 2026 Zenas BioPharma presentará nuevos datos del ensayo de fase 3 INDIGO que evalúa Obexelimab en la enfermedad relacionada con IgG4 en el 6º Simposio Internacional sobre la Enfermedad Relacionada con IgG4, y en la Convergencia ACR 2026 Benzinga 2026.09.22 11:15 (GMT+0) Open on Benzinga Other news If You Invested $1000 In SPDR Gold MiniShares Trust Stock 5 Years Ago, You Would Have This Much Today $100 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Bitcoin Faces Historic Capitulation Levels: Can $62,000 Support Hold? $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg
If You Invested $1000 In SPDR Gold MiniShares Trust Stock 5 Years Ago, You Would Have This Much Today